Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil™ is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Collagen-based biodegradable matrices for localized drug delivery More
Antroquinonol® is a non-toxic, highly effective cancer treatment agent, developed using natural organic chemistry. More
Biotechnology Product for Wound Healing More
An active ingredient purified from herbal material for the treatment of skin disorders and for wound-healing. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Acne
- Actinic keratosis
- Alopecia
- Bacterial infection
- Burns
- Chronic idiopathic urticaria
- Cosmetic procedures
- Dermal ulcers
- Dermatitis, allergic
- Dermatitis, atopic
- Dermatological (other)
- Dermatosis
- Eczema
- Fungal infection
- Hirsutism
- Human B19 parvovirus
- Hyperkeratosis
- Ichthyosis
- Impetigo
- Insect bite
- Keloids
- Lupus
- Male pattern baldness
- Paget's disease
- Photodamage
- Pruritis
- Psoriasis
- Scleroderma
- Shingles
- Skin infection (other)
- Ulcer, diabetic
- Urticaria
- Wound healing
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us